Self-assembled peptide nanoparticle and use thereof

Patent metadata

Field	Value
Publication number	US-2022088221-A1
Application number	US-202017422309-A
Country	US
Kind code	A1
Filing date	Jan 13, 2020
Priority date	Jan 12, 2019
Publication date	Mar 24, 2022
Grant date	—

Abstract

Disclosed are self-assembling nanoparticle compositions that comprise a plurality of cationic cell penetrating peptides, each covalently linked to a hydrophobic therapeutic molecule (e.g., an antigenic peptide, mRNA, siRNA, DNA, or the like), and optionally, non-covalently bound to at least one TLR (Toll-like receptor) ligand. Also disclosed are methods for use of the nanoparticle compositions in the treatment, prophylaxis, and/or the amelioration of one or more symptoms of a mammalian disease, including, without limitation, cancer, infection, inflammation, and related diseases and abnormal conditions.

First claim

What is claimed is:

1 . A composition comprising:
(a) a population of nanoparticles, self-assembling at neutral pH, and comprised of a plurality of cationic cell-penetrating peptides covalently linked to a hydrophobic therapeutic peptide ligand; (b) a pharmaceutically-acceptable buffer, diluent, carrier, or vehicle.

2 . The composition in accordance with claim 1 , wherein the nanoparticles further comprise a negatively-charged molecule such as mRNA, siRNA, dsRNA, RNA, DNA, or any combination thereof, or a hydrophobic peptide such as MPLA.

3 . The composition in accordance with claim 1 or claim 2 , further comprising an amphiphobic or amphipathic peptide, such as CPP-TAT covalently linked to a therapeutic peptide, such as NY-ESO-1 (SEQ ID NO:1) or TRP-2 (SEQ ID NO:2).

4 . The composition in accordance with any preceding claim, adapted and configured for increasing IFN-I expression, when introduced into suitable mammalian cells; preferably for increasing expression of IFN-α4 or IFN-β.

5 . The composition in accordance with any preceding claim, comprised within an isolated population of mammalian cells, such as tumor cells or dendritic cells.

6 . The composition in accordance with any preceding claim, comprising one or more cationic cell penetrating peptides as disclosed in any one of SEQ ID NO:3 to SEQ ID NO:8 or SEQ ID NO:11 to SEQ ID NO:16.

7 . The composition in accordance with any preceding claim, further comprising: (c) a chemotherapeutic agent, an immunomodulating agent, a neuroactive agent, an anti-inflammatory agent, an anti-lipidemic agent, a hormone, a receptor agonist, a receptor antagonist, an anti-infective agent, an antibody, an antigen-binding fragment of an antibody, a ribozyme, a cofactor, a steroid, or any combination thereof.

8 . The composition in accordance with claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, 5-fluorouracil, docetaxel, paclitaxel, trastuzumab, methotrexate, epirubicin, cisplatin, carboplatin, vinorelbine, capecitabine, gemcitabine, mitoxantrone, isabepilone, eribulin, lapatinib, carmustine, a nitrogen mustard, a sulfur mustard, a platin tetranitrate, vinblastine, etoposide, camptothecin, and any combination thereof.

9 . The composition in accordance with any preceding claim, further comprising an adjuvant.

10 . The composition in accordance with any preceding claim, further comprising an antigen, an antigenic polypeptide, or an antigenic peptide fragment thereof.

11 . The composition in accordance with any preceding claim, 1) formulated with a population of liposomes, nanoparticles, or microparticles; or 2) admixed with one or more surfactants, niosomes, ethosomes, transferosomes, phospholipids, or sphingosomes.

12 . The composition in accordance with any preceding claim, admixed with one or more pharmaceutically-acceptable carriers, buffers, diluents, vehicles, or excipients.

13 . The composition in accordance with any preceding claim, formulated for systemic administration to a mammal, and preferably, for intravenous administration to a human.

14 . The composition in accordance with any preceding claim, adapted and configured as part of a therapeutic kit that comprises the composition, and at least a first set of instructions for administration of the composition to a human in need thereof.

15 . The composition in accordance with any preceding claim, for use in therapy, prophylaxis, or amelioration of one or more symptoms of a mammalian disease, disorder, dysfunction, deficiency, defect, trauma, injury, or abnormal condition.

16 . The composition in accordance with any preceding claim, for use in the therapy, prophylaxis, or amelioration of one or more symptoms of human cancer or infection.

17 . An isolated population of mammalian cells comprising the composition in accordance with any preceding claim.

18 . The isolated population of mammalian cells in accordance with claim 17 , characterized as human dendritic cells.

19 . Use of a composition in accordance with any one of claims 1 to 16 , in the manufacture of a medicament for treating or ameliorating at least one symptom of a cancer or an infection in a mammalian subject.

20 . Use in accordance with claim 19 , wherein the mammalian subject is a human, a non-human primate, a companion animal, an exotic, or a livestock.

21 . A kit comprising: 1) a composition in accordance with any one of claims 1 to 16 ; and 2) instructions for administering the composition to a mammal in need thereof, as part of a regimen for the prevention, diagnosis, treatment, or amelioration of one or more symptoms of a disease, a dysfunction, an abnormal condition, or a trauma in the mammal.

22 . A method of treating or ameliorating one or more symptoms of cancer or an infection in an animal in need thereof, the method comprising administering to the animal an effective amount of a composition in accordance with any one of claims 1 to 16 , for a time sufficient to treat or ameliorate the one or more symptoms of the cancer or the infection in the animal.

23 . The method in accordance with claim 22 , wherein the cancer is diagnosed as, or is identified as, a refractory, a metastatic, a relapsed, or a treatment-resistant cancer.

24 . The method in accordance with claim 22 or 23 , wherein the animal is human.

25 . The method in accordance with any one of claims 22 to 24 , wherein the composition is administered systemically to the animal, in a single administration, or in a series of multiple administrations over a period of from one or more days, over a period of one or more weeks, or over a period of one or more months or longer.

26 . The method in accordance with any one of claims 22 to 25 , wherein the composition further comprises a second distinct chemotherapeutic agent, or a second distinct population of self-assembling nanoparticles that comprises a second distinct therapeutic agent.

27 . A method of administering a diagnostic, therapeutic, or prophylactic agent to one or more cells, tissues, organs, or systems of a mammalian subject in need thereof, comprising administering to the subject an effective amount of the composition of in accordance with any one of claims 1 to 16 .

28 . The method in accordance with claim 27 , wherein the one or more cells are human dendritic cells.

29 . The method in accordance with claim 27 , wherein the one or more tissues is tumoral.

30 . A method of providing a therapeutic composition to at least one cell, at least one tissue, or at least one organ of a patient in need thereof, comprising administering to a patient in need thereof, an amount of a composition in accordance with any one of claims 1 to 16 , or an isolated population of mammalian cells in accordance with claim. 17 or claim 18 , and for a time effective to provide the therapeutic composition to at least one cell, at least one tissue, or at least one organ of the patient.

Assignees

• Methodist Hospital

Inventors

• Wang Rongfu
• Wang Yicheng
• Zhu Motao
• Zhao Ruifang

Classifications

• A61K40/4269

  NY-ESO · CPC title

• A61K40/4245

  Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2] · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/24

  Antigen-presenting cells [APC] · CPC title

• A61K40/19

  Dendritic cells · CPC title